Posted by Michael Wonder on 22 Feb 2022
BeiGene announces European Medicines Agency acceptance of applications for Brukinsa (zanubrutinib) in chronic lymphocytic leukaemia and marginal zone lymphoma
22 February 2022 - The CLL filing is supported by two global Phase 3 trials of Brukinsa in chronic lymphocytic leukaemia covering both treatment naïve and relapsed or refractory patient populations.
BeiGene today announced that the EMA has accepted for review two new indication applications for its BTK inhibitor Brukinsa (zanubrutinib) for the treatment of patients with chronic lymphocytic leukaemia and for the treatment of patients with marginal zone lymphoma.
